Providing access to holistic management for Hemophilia treatment in India.
Pushing the boundaries in the treatment of Hemophilia

Hemophilia is an inherited single gene disorder with an incidence of 1 per 10,000 births; affecting men (women are only carriers) in which the blood doesn't clot normally. With more than two lakh cases, India is home to the second largest population of people with Hemophilia. Blood contains many proteins called clotting factors that help stop bleeding. People with hemophilia (PwH) have low levels of either factor VIII (8) or factor IX (9). The severity of hemophilia that a person has is determined by the amount of factor in the blood. The lower the amount of the clotting factor, the more likely it is that bleeding will occur which can lead to serious health problems. This means the person tends to bleed for a longer time after an injury, and they are more susceptible to internal bleeding. This bleeding can be fatal if it occurs within a vital organ.2


The only approved subcutaneous Hemophilia A treatment

Hemlibra is the standard of care for the treatment of people with hemophilia A. Hemlibra has been approved in India for Hemophilia A with or without factor VIII inhibitors. It is indicated as a prophylactic (preventive) treatment to prevent or reduce the frequency of bleeding episodes for patients across all age groups; Hemlibra is also the first subcutaneous drug for hemophilia A that you can self administer as an injection under your skin. There are several possible dosing schedules, including weekly, every two weeks, or every four weeks intended to allow patients and their physicians to choose the option that’s right for them, based on their lifestyle and preferences.

Hemlibra has been studied in one of the largest pivotal clinical trial programmes in hemophilia A with and without factor VIII inhibitors. Hemlibra is approved in more than 100 countries worldwide and since its initial FDA approval, more than 15,000 people have received Hemlibra globally.

Hemophilia is a serious bleeding disorder. It causes spontaneous bleeding in joints and muscles; it affects 1 in 10,000 live births that is one in 5,000 live male births. Most of them are crippled by the time they are teenagers. They are treated with factor VIII or factor IX injections. It has to be given through the vein 2-3 times/week throughout their life. This is very difficult, especially for children. With recent advances in prophylaxis, PWH have renewed hope of living a significantly better quality of life. Drugs like Emicizumab, and others are given subcutaneously (under the skin) just like insulin, once a week to once a month. It is a lot simpler nowadays, making the lives of PWH free of pain and disability.
Dr. Cecil Ross
Professor & Head Hematology St. John's Medical College Hospital, Bangalore

Safety Update Information for Healthcare Professionals

I understand the following:

  1. The information contained in this Letter is for the sole purpose of use and knowledge of Healthcare Professionals (HCPs) Only.

  2. If any Individual other than HCPs access the information contained in this Letter and act thereon, then Roche will not be liable for any consequences in relation thereto.

  3. Patients and their relatives should not access the information contained in this Letter. They are advised to consult their treating physicians.

  4. I hereby confirm that I am a Healthcare Professional and agree to the terms and conditions mentioned above.

Continue to Local Prescribing Information


  1. https://www.udayavani.com/english-news/this-world-hemophilia-day-lets-pledge-to-raise-awareness-on-one-of-the-most-under-diagnosed-rare-diseases-in-india#:~:text=India%20has%20the%20second%2Dhighest,and%20scarcity%20of%20diagnostic%20facilities



More stories

See all stories

More focus areas

View all focus areas

please be aware that you are leaving this website.